AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
RxSight, Inc.
Video analysis: RXST
All videosNo video analysis for this stock yet. Request one from our team.
News: RXST
85,838 Shares in RxSight, Inc. $RXST Purchased by Corient Private Wealth LP
Corient Private Wealth LP bought a new stake in shares of RxSight, Inc. (NASDAQ: RXST) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 85,838 shares of the company's stock, valued at approximately $414,000. Corient Private Wealth LP owned 0.21% of RxSight at the
BlackRock Inc. Purchases Shares of 5,790,408 RxSight, Inc. $RXST
BlackRock Inc. acquired a new stake in RxSight, Inc. (NASDAQ: RXST) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 5,790,408 shares of the company's stock, valued at approximately $27,910,000. BlackRock Inc. owned 13.99% of RxSight at the end
RxSight, Inc. to Participate in the Wells Fargo Healthcare Conference
ALISO VIEJO, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced that management is scheduled to participate in the Wells Fargo Healthcare Conference on Wednesday, September 9, 2026, at 9:30 a.m. ET in Boston, Massachusetts. A live and archived webcast of the presentation will be available on the Company's investor relations website at https://investors.rxsight.com/.
Head-To-Head Comparison: RxSight (NASDAQ:RXST) and Futureworld (OTCMKTS:FWDG)
RxSight (NASDAQ: RXST - Get Free Report) and Futureworld (OTCMKTS:FWDG - Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, earnings, dividends, profitability and risk. Risk and Volatility RxSight has a beta of 1.13, suggesting
RxSight, Inc. (RXST) Q2 2026 Earnings Call Transcript
RxSight, Inc. (RXST) Q2 2026 Earnings Call Transcript
RxSight Q2 Earnings Call Highlights
RxSight NASDAQ: RXST reported second-quarter revenue of $33.7 million, including $6.5 million recognized under its strategic collaboration with Alcon, while management withdrew its full-year 2026 financial guidance as new Chief Executive Officer Aziz Mottiwala conducts a broader assessment of the business.
RxSight Q2 Earnings Call Highlights
RxSight (NASDAQ: RXST) reported second-quarter revenue of $33.7 million, including $6.5 million recognized under its strategic collaboration with Alcon, while management withdrew its full-year 2026 financial guidance as new Chief Executive Officer Aziz Mottiwala conducts a broader assessment of the business. Excluding the Alcon-related revenue, product sales were $27.2 million, down 19% from the prior-year period.
RxSight, Inc. (RXST) Reports Q2 Loss, Beats Revenue Estimates
RxSight, Inc. (RXST) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to a loss of $0.08 per share a year ago.
Similar companies
-
NeuroPace, Inc.
NPCE
·
NASDAQ
Compare
-
Tactile Systems Technology, Inc.
TCMD
·
NASDAQ
Compare
-
OrthoPediatrics Corp.
KIDS
·
NASDAQ
Compare
-
Butterfly Network, Inc.
BFLY
·
New York Stock Exchange
Compare
-
Treace Medical Concepts, Inc.
TMCI
·
NASDAQ
Compare
-
DiaMedica Therapeutics Inc.
DMAC
·
NASDAQ
Compare